Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project

Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project

Extended-phase anticoagulation with direct oral Xa inhibitors (OAXI) is suggested in patients with cancer-associated venous thromboembolism (CAT). We report on patients enrolled in the MAC (Monitoring AntiCoagulants) Project, given rivaroxaban as extended-phase anticoagulation after CAT. The primary...

Full description

Bibliographic Details
Main Authors: Enrico Bernardi, Giuseppe Camporese, Cristiano Bortoluzzi, Franco Noventa, Davide Ceccato, Chiara Tonello, Stefania Vohong, Elena Campello, Chiara Simion, Egidio Imbalzano, Pierpaolo Di Micco, Elena Callegari, Paolo Simioni
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Life
Subjects:
cancer-related venous thromboembolism
factor Xa inhibitors
extended-phase anticoagulation
real-life
Online Access:https://www.mdpi.com/2075-1729/12/11/1725

Internet

https://www.mdpi.com/2075-1729/12/11/1725

Similar Items